EcoDrugPlus

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSCCRG00000048940
Gene Symbol: CFTR
1 Cross references
214 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSCCRG00000076147
Gene Symbol: DNMT1
1 Cross references
208 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSCCRG00000070015
Gene Symbol: DNMT1
1 Cross references
209 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSCCRG00000032166
Gene Symbol: TOP1
1 Cross references
201 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSCCRG00000046122
Gene Symbol: TOP2A
1 Cross references
207 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSCCRG00000076497
Gene Symbol: TOP2B
1 Cross references
206 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSCCRG00000030918
Gene Symbol: TOP2B
1 Cross references
206 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSCCRG00000043096
Gene Symbol: TOP1A
1 Cross references
205 Possible Orthologues:

Dna Topoisomerase Ia

Ensembl ID : ENSCCRG00000076066
Gene Symbol: TOP1A
1 Cross references
205 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSCCRG00000019370
Gene Symbol: EML4
1 Cross references
209 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion B

Ensembl ID : ENSCCRG00000022403
Gene Symbol: FAUB
1 Cross references
237 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion B

Ensembl ID : ENSCCRG00000025151
Gene Symbol: FAUB
1 Cross references
237 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).